Longboard Pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases.
Longboard’s proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.
Longboard, formerly known as Arena Neuroscience, was a wholly-owned subsidiary of Arena Pharmaceuticals, Inc. until its launch in October 2020. Longboard’s compounds were discovered and evolved out of Arena’s validated world-class GPCR research engine.